ePrints

Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain

Lookup NU author(s): Dr Gajanan Sherbet

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2014 Published by Elsevier Ireland Ltd. HER2 positive breast cancers have been shown to have a greater propensity to metastasise to the brain. This may be due to several reasons, including the creation of a "sanctuary-site" for tumour in the brain following trastuzumab therapy. Elucidating the mechanism of this phenomenon may aid the prevention or intervention and treatment of such metastases, but research is limited by the deficiency and diminished access of CNS tissue. However, CNS penetrable HER2 receptor antagonists such as lapatinib and intrathecal administration of trastuzumab might benefit patients, and are worthy of further investigation. New avenues of molecular approach have focused on manipulating signal transduction system involved in HER2 function. The importance of systemic therapies and those targeted to metastatic lesions is emphasised and evaluated here.

Publication metadata

Author(s): Patil A, Sherbet GV

Publication type: Note

Publication status: Published

Journal: Cancer Letters

Year: 2015

Volume: 358

Issue: 2

Pages: 93-99

Print publication date: 28/03/2015

Online publication date: 18/12/2014

Acceptance date: 11/12/2014

ISSN (print): 0304-3835

ISSN (electronic): 1872-7980

Publisher: Elsevier Ireland Ltd

URL: https://doi.org/10.1016/j.canlet.2014.12.026

DOI: 10.1016/j.canlet.2014.12.026

PubMed id: 25529010

Share